US court rejects Novo Nordisk’s challenge to Medicare drug pricing plan

Court ruling allows Medicare to negotiate prices for larger number of drugs

An appeals court declined to limit the government's ability to lump drugs with the same ingredient together.

Novo Nordisk loses bid to halt Medicare price negotiations

Novo Nordisk (NVO) stock is in focus as a federal appeals court denies the company's bid to challenge Medicare drug pricing negotiations. Read more here.

Court Upholds Medicare Drug Price Negotiation Program - Legal Reader

Appeals court rules government lawfully included Novo insulin in negotiations.

Appeals Court Rejects Novo Nordisk Challenge to Medicare Drug Pricing Plan

A federal appeals court on Oct. 6 rejected a challenge from Novo Nordisk to the Medicare drug pricing plan included in the Biden-era Inflation Reduction Act (IRA). The plan does not violate the Constitution’s First Amendment, a unanimous panel of judges from the U.S. Court of Appeals for the Third Circuit said in a 22-page decision. They also turned away other arguments from Novo Nordisk, in part because the law enacting the plan precludes judic…

US court rejects Novo Nordisk’s challenge to Medicare drug pricing plan

By Diana Novak Jones CHICAGO (Reuters) -A federal appeals court on Monday rejected Novo Nordisk’s challenge to the U.S. government’s program that gives its Medicare health insurance plan the power to negotiate lower drug prices, the latest in a barrage of lawsuits brought by drugmakers to fail. The Philadelphia-based 3rd U.S. Circuit Court of Appeals affirmed a lower court’s ruling dismissing the Danish drugmaker’s challenge to the program and t…

Third Circuit appeals court tosses Novo Nordisk’s IRA case

A federal appeals court rejected Novo Nordisk’s challenge against Medicare drug price negotiations on Monday, marking another loss for the pharma industry in a long-running legal battle that could be headed for the Supreme Court.